PPBT Purple Biotech Corp Total Debt to Capital

Purple Biotech (PPBT) develops drugs for targeted action on solid tumors, relying on patent protection for its developments. This GURU.Markets chart for the total debt-to-equity metric is fixed at 0.01. The company's financial position depends on the outcome of pancreatic therapy tests and the willingness of major industry players to acquire the rights to these innovations.

High expenditures on biological staff and the patenting of methods to combat solid tumors require significant capital investments from Purple Biotech. This debt-to-equity ratio compares total liabilities to equity, demonstrating the degree of financial leverage used to fund R&D processes, which allows investors to assess the debt load risk and the company's overall cost of capital.